RJA
GLMD icon

Raymond James & Associates’s Galmed Pharmaceuticals GLMD Stock Holding History

Raymond James & Associates’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-767
Closed -$58.9K – 3888
2023
Q1 		$58.9K Hold
767
– – ﹤0.01% 3719
2022
Q4 		$69K Sell
767
-99
-11% -$6.48K ﹤0.01% 3691
2022
Q3 		$49K Sell
866
-9
-1% -$768 ﹤0.01% 3708
2022
Q2 		$102K Sell
875
-252
-22% -$41.8K ﹤0.01% 3676
2022
Q1 		$323K Sell
1,127
-4
-0.4% -$1.13K ﹤0.01% 3370
2021
Q4 		$370K Sell
1,131
-145
-11% -$65.5K ﹤0.01% 3313
2021
Q3 		$641K Buy
1,276
+121
+10% +$63.5K ﹤0.01% 2883
2021
Q2 		$632K Buy
1,155
+327
+39% +$178K ﹤0.01% 2916
2021
Q1 		$511K Buy
828
+48
+6% +$33.2K ﹤0.01% 3001
2020
Q4 		$437K Sell
780
-490
-39% -$306K ﹤0.01% 2905
2020
Q3 		$807K Sell
1,270
-1,700
-57% -$1.39M ﹤0.01% 2308
2020
Q2 		$2.56M Buy
2,970
+1,058
+55% +$892K ﹤0.01% 1575
2020
Q1 		$1.19M Sell
1,912
-330
-15% -$314K ﹤0.01% 1864
2019
Q4 		$2.33M Buy
2,242
+829
+59% +$712K ﹤0.01% 1736
2019
Q3 		$1.22M Buy
1,413
+780
+123% +$782K ﹤0.01% 2072
2019
Q2 		$838K Buy
633
+148
+31% +$191K ﹤0.01% 2329
2019
Q1 		$713K Buy
485
+6
+1% +$8.72K ﹤0.01% 2407
2018
Q4 		$589K Buy
479
+77
+19% +$134K ﹤0.01% 2445
2018
Q3 		$984K Buy
+402
New +$941K ﹤0.01% 2268

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TFGT
TS Financial Group (TSFG) Lake Forest, Illinois $794M AUM 24.65% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BCM
Bourgeon Capital Management Darien, Connecticut $679M AUM 50.89% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Raymond James & Associates's GLMD Position: Q2 2023 in Review

Raymond James & Associates sold out of Galmed Pharmaceuticals (GLMD) in Q2 2023, closing a stake of 767 shares — an estimated $58.9K sold.

Raymond James & Associates first reported a position in GLMD in Q3 2018 and held it in 19 quarters. The position peaked at $2.56M in Q2 2020. 11 funds tracked by Wall St. Rank hold GLMD as of Q2 2023.

  • Raymond James & Associates reported no remaining Galmed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Raymond James & Associates sold 767 Galmed Pharmaceuticals shares in Q2 2023, an estimated $58.9K.
  • Raymond James & Associates first reported a position in Galmed Pharmaceuticals in Q3 2018 and held it in 19 quarters.
  • Raymond James & Associates's Galmed Pharmaceuticals position peaked at $2.56M in Q2 2020.
  • 11 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2023.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.